AUTHOR=Clark Edward A. , Giltiay Natalia V. 

TITLE=CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity

JOURNAL=Frontiers in Immunology

VOLUME=9

YEAR=2018

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02235

DOI=10.3389/fimmu.2018.02235

ISSN=1664-3224

ABSTRACT=<p>CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (<xref ref-type="bibr" rid="B1">1</xref>). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (<xref ref-type="bibr" rid="B2">2</xref>–<xref ref-type="bibr" rid="B4">4</xref>). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE).</p>